- Reports Revenue of $2.4 Billion, Growing 1%, and Net Income of $721 Million, or $1.63 per Diluted Share, Increasing 6% and 9%, Respectively, on a Reported Basis for Third Quarter 2025
- Delivers 4% Organic Operational Growth in Revenue and 9% Organic Operational Growth in Adjusted Net Income for Third Quarter 2025
- Reports Adjusted Net Income of $754 Million, or Adjusted Diluted EPS of $1.70, for Third Quarter 2025
- Revises Full Year 2025 Revenue Guidance to $9.400 - $9.475 Billion with Organic Operational Revenue Growth of 5.5% to 6.5% Based on Broader Macro Trends and the Operational Environment
- Narrows Full Year 2025 Guidance for Organic Operational Growth in Adjusted Net Income to 5.5% to 7.0% to Reflect Continued Disciplined Execution
- Maintains Guidance for Diluted EPS on an Adjusted Basis of $6.30 to $6.40
PARSIPPANY, N.J.--(BUSINESS WIRE)--$ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) today reported its financial results for the third quarter of 2025.
The company reported revenue of $2.4 billion for the third quarter of 2025, an increase of 1% compared with the third quarter of 2024. On an organic operational1 basis, revenue for the third quarter of 2025 increased 4% compared with the third quarter of 2024. Net income for the third quarter of 2025 was $721 million, or $1.63 per diluted share, an increase of 6% and 9%, respectively, on a reported basis.
Adjusted net income2 for the third quarter of 2025 was $754 million, or $1.70 per diluted share, an increase of 5% and 8%, respectively, on a reported basis, and an increase of 9% and 12%, respectively, on an organic operational basis. Adjusted net income for the third quarter of 2025 excludes the net impact of $33 million for purchase accounting adjustments, acquisition and divestiture-related costs and certain significant items.
EXECUTIVE COMMENTARY
“We reported 4% organic operational revenue growth and 9% growth in adjusted net income on an organic operational basis, thanks to the relentless focus and consistent execution of our colleagues across the world," said Kristin Peck, Chief Executive Officer of Zoetis. “While growth moderated in the third quarter in line with our expectations, we achieved significant regulatory milestones, including major new product approvals, geographic expansions and differentiating lifecycle innovations across products and species. With our manufacturing excellence, strong customer relationships and a robust pipeline, we are well positioned to advance animal care, bring new products to market and deliver sustainable growth and value for our shareholders.”
QUARTERLY HIGHLIGHTS
Zoetis organizes and manages its commercial operations across two segments: United States (U.S.) and International. Within these segments, the company delivers a diverse portfolio of products for companion animals and livestock, tailored to local trends and customer needs. In the third quarter of 2025:
- Revenue in the U.S. segment was $1.3 billion, a decrease of 2% on a reported basis and an increase of 3% on an organic operational basis compared with the third quarter of 2024. Sales of the company's innovative companion animal products were flat for the quarter. Growth in the company's parasiticides portfolio, including Simparica® and Revolution® franchises, diagnostics and key dermatology portfolio, including Apoquel® Chewable, were offset by a decline in the company's monoclonal antibody (mAb) products for osteoarthritis (OA) pain, Librela® for dogs and Solensia® for cats. Sales of livestock products declined 9% on a reported basis in the quarter, largely due to the divestiture of the medicated feed additive (MFA) product portfolio and related assets. On an organic operational basis, sales of livestock products increased 14% with strength in the cattle portfolio driven primarily by improved supply of ceftiofur products and growth across the broader livestock portfolio, primarily in vaccines.
- Revenue in the International segment was $1.1 billion, a 3% increase on a reported basis and a 6% increase on an organic operational basis compared with the third quarter of 2024. Sales of the company's innovative companion animal products grew 8% on a reported basis and 4% operationally3. Growth in the quarter was driven by the company's parasiticides portfolio, including both Simparica and Revolution/Stronghold® franchises, as well as key dermatology products Apoquel® and Cytopoint®. Sales of livestock products declined 2% on a reported basis, due to the divestiture of the MFA product portfolio and related assets. Sales of livestock products increased 8% on an organic operational basis, driven by broad-based growth across all core species.
INVESTMENTS IN GROWTH
Zoetis continues to advance care for animals across the globe with a robust pipeline fueled by lifecycle innovation, geographic expansion and disruptive innovation. As noted at the JP Morgan Healthcare Conference in January, the company expects to receive a significant approval in a major market every year for the next several years. The company will host an Innovation webcast on Tuesday, December 2 at 8:30 a.m. ET to provide investors with updates and progress related to its pipeline, and details about Zoetis’ strategic approach to addressing unmet needs, industry-leading R&D capabilities and potential for long-term growth.
Expanding Company’s OA Pain Franchise with Lenivia® and Portela® Regulatory Milestones
Since its last quarterly earnings announcement, Zoetis received approval in Canada for Lenivia, the first long-acting monoclonal antibody to alleviate OA pain in dogs for up to three months with one injection. This significant milestone comes after more than a decade of science and research to address the unmet needs of this market. Nearly 40% of dogs of any age or size may be affected by OA pain4, 5, and chronic pain can negatively impact dogs’ movement, sleep, behavior and social relationships6. Zoetis expects to launch Lenivia in Canada in 2026. Lenivia also received a positive opinion from the Committee for Veterinary Medicinal Products (CVMP) of the European Medicines Agency (EMA), with marketing authorization expected in the fourth quarter of 2025. The company anticipates making Lenivia commercially available in the EU in 2026.
Portela, the first monoclonal antibody therapy with a three-month dosing interval approved for the alleviation of pain associated with OA in cats, received marketing authorization in the EU. This important milestone addresses unmet needs in the market, as up to 40% of all cats have clinical signs of OA7, 8. Zoetis anticipates making Portela commercially available in the EU in 2026.
Continued Expansion of Key Dermatology and Simparica Franchises
The company continues to expand its differentiated dermatology offerings around the world with the approval of Apoquel Chewable in Chile and the labeling of Cytopoint for the treatment of allergic dermatitis in Brazil.
In parasiticides, Simparica Trio® received approval in Brazil and gained new label indications in various international markets, demonstrating the company’s commitment to continued lifecycle innovation to address the unmet needs of its customers. New label indications include:
- In Australia: for the treatment and control of two additional hookworm species and to kill heartworm microfilaria and A. aegypti mosquitoes. This is the first heartworm preventative product in Australia to have a claim for microfilaricidal activity.
- In Canada: to prevent Dipylidium caninum (flea tapeworm) infections by killing Ctenocephalides felis vector fleas in treated dogs. With this approval, Simparica Trio is the only canine combination parasiticide indicated to prevent flea tapeworm infections, at the source, by killing vector fleas before transmission.
- In the UK: to prevent lungworm disease (angiostrongylosis).
Innovating at the Point-of-Care with Diagnostics
Following a successful U.S. launch, the company expanded its new premium point-of-care hematology analyzer, Vetscan® Opticell™, into the EU. This first-of-its-kind tool offers veterinary healthcare teams significant time, cost and space savings – leading to better patient outcomes and a more efficient clinic. The innovative AI-powered classification technology offers a more advanced option for Complete Blood Count (CBC) analysis, providing lab-quality results in the clinic.
Supporting Livestock Customers
To address an urgent threat facing U.S. livestock producers, Zoetis received a conditional approval from the Food and Drug Administration (FDA) for Dectomax®-CA1 Injectable for the prevention and treatment of New World screwworm myiasis in cattle. This new label makes it the first and only parasite control product with conditional approval to help control this economically devastating pest.
Synovex® Primer™ received approval in Canada for an additional claim to increase rate of weight gain in growing beef steers and heifers on pasture. It also received approval in Mexico for use on pasture, confinement and in the backgrounder phase. In the UK, the company received approval for a needle-free microdose of Suvaxyn® PRRS, a vaccine that helps prevent porcine respiratory and reproductive syndrome.
Strengthening U.S. Commercial Execution
Building on the continued strength of its companion animal franchises and the critical role they play in veterinary practices, Zoetis is evolving its U.S. go-to-market strategy to reinforce its market leadership, better serve customers and operate more efficiently. This includes realigning the U.S. field structure to create a more simplified and agile commercial organization and deliver an elevated customer experience. The company expects these actions to expand its reach, further deepen its customer relationships and help extend the lifecycle of its key franchises.
FINANCIAL GUIDANCE
Zoetis is updating its full year 2025 guidance based on the broader macro trends and operational environment in the back half of the year, and the company's continued disciplined approach to cost management and investment.
- Revenue between $9.400 billion to $9.475 billion (organic operational growth of 5.5% to 6.5%)
- Reported net income between $2.625 billion to $2.665 billion
- Adjusted net income between $2.800 billion to $2.840 billion (organic operational growth of 5.5% to 7.0%)
- Reported diluted EPS of $5.90 to $6.00
- Adjusted diluted EPS between $6.30 to $6.40
This guidance reflects foreign exchange rates as of late October and the impact of enacted and assumptions on announced tariffs. Additional details on guidance are included in the financial tables and will be discussed on the company's conference call.
WEBCAST & CONFERENCE CALL DETAILS
Zoetis will host a webcast and conference call at 8:30 a.m. ET today, during which company executives will review third quarter 2025 results, discuss financial guidance and respond to questions from financial analysts. Investors and the public may access the live webcast and corresponding slides by visiting the Zoetis website at https://investor.zoetis.com/events-presentations. A replay of the webcast will be archived and made available on November 4, 2025.
About Zoetis
As the world’s leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After innovating ways to predict, prevent, detect, and treat animal illness for more than 70 years, Zoetis continues to stand by those raising and caring for animals worldwide – from veterinarians and pet owners to livestock producers. The company’s leading portfolio and pipeline of medicines, vaccines, diagnostics and technologies make a difference in over 100 countries. A Fortune 500 company, Zoetis generated revenue of $9.3 billion in 2024 with approximately 13,800 employees. For more information, visit www.zoetis.com.
1 Organic operational results (a non-GAAP financial measure) is defined as results excluding the impact of foreign exchange and certain acquisitions and divestitures.
2 Adjusted net income and its components and adjusted diluted earnings per share (non-GAAP financial measures) are defined as reported net income and reported diluted earnings per share, excluding purchase accounting adjustments, acquisition and divestiture-related costs and certain significant items.
3 Operational results (a non-GAAP financial measure) is defined as results excluding the impact of foreign exchange.
4 Wright A, Amodie DM, Cernicchiaro N, et al. Identification of canine osteoarthritis using an owner-reported questionnaire and treatment monitoring using functional mobility tests. J Small Anim Pract. 2022;63(8):609-618.
5 Enomoto M, de Castro N, Hash J, et al. Prevalence of radiographic appendicular osteoarthritis and associated clinical signs in young dogs. Sci Rep. 2024;14(1):2827.
6 Lascelles BDX, Brown DC, Conzemius MG, Gill M, Oshinsky ML, Sharkey ML. Measurement of chronic pain in companion animals: discussions from the Pain in Animals Workshop (PAW) 2017. Vet J. 2019;250:71-78.
7 Enomoto M, Mantyh PW, Murrell J, Innes JF, Lascelles BDX. Anti-nerve growth factor monoclonal antibodies for the control of pain in dogs and cats. Vet Rec. 2019;184(1):23.
8 L.I. Slingerland, H.A.W. Hazewinkel, B.P. Meij, Ph. Picavet, G. Voorhout, Cross-sectional study of the prevalence and clinical features of osteoarthritis in 100 cats. The Veterinary Journal, Volume 187, Issue 3, 2011, Pages 304-309.
DISCLOSURE NOTICES
Forward-Looking Statements: This press release contains forward-looking statements, which reflect the current views of Zoetis with respect to: business plans or prospects, future operating or financial performance, future guidance, future operating models; R&D costs; timing and likelihood of success; expectations regarding products, product approvals or products under development and expected timing of product launches; expectations regarding competing products; expectations regarding financial impact of divestitures; disruptions in our global supply chain; expectations regarding the performance of acquired companies and our ability to integrate new businesses; expectations regarding the financial impact of acquisitions; future use of cash, dividend payments and share repurchases; foreign exchange rates, tax rates, tariffs, changes in tax regimes and laws and any changes thereto; and other future events. These statements are not guarantees of future performance or actions. Forward-looking statements are subject to risks and uncertainties. If one or more of these risks or uncertainties materialize, or if management's underlying assumptions prove to be incorrect, actual results may differ materially from those contemplated by a forward-looking statement. Forward-looking statements speak only as of the date on which they are made. Zoetis expressly disclaims any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. A further list and description of risks, uncertainties and other matters can be found in our most recent Annual Report on Form 10-K, including in the sections thereof captioned “Forward-Looking Statements and Factors That May Affect Future Results” and “Item 1A. Risk Factors,” in our Quarterly Reports on Form 10-Q and in our Current Reports on Form 8-K. These filings and subsequent filings are available online at www.sec.gov, www.zoetis.com, or on request from Zoetis.
Use of Non-GAAP Financial Measures: We use non-GAAP financial measures, such as adjusted net income, adjusted diluted earnings per share, operational results (which exclude the impact of foreign exchange) and organic operational results (which exclude the impact of foreign exchange and certain acquisitions and divestitures), to assess and analyze our results and trends and to make financial and operational decisions. We believe these non-GAAP financial measures are also useful to investors because they provide greater transparency regarding our operating performance. The non-GAAP financial measures included in this press release should not be considered alternatives to measurements required by GAAP, such as net income, operating income, and earnings per share, and should not be considered measures of liquidity. These non-GAAP financial measures are unlikely to be comparable with non-GAAP information provided by other companies. Reconciliations of non-GAAP financial measures and the most directly comparable GAAP financial measures are included in the tables accompanying this press release and are posted on our website at www.zoetis.com.
Internet Posting of Information: We routinely post information that may be important to investors on the 'Investor Relations' section of our website at www.zoetis.com, as well as on LinkedIn, Facebook, X (formerly Twitter) and YouTube. We encourage investors and potential investors to consult our website regularly and to follow us on social media for company news and information.
ZTS-COR
ZTS-IR
ZTS-FIN
ZOETIS INC. CONDENSED CONSOLIDATED STATEMENTS OF INCOME(a) (UNAUDITED) (millions of dollars, except per share data) |
||||||||||||||||||||
|
Three Months Ended |
|
|
|
Nine Months Ended |
|
|
|||||||||||||
September 30, |
|
|
|
September 30, |
|
|
||||||||||||||
2025 |
|
|
2024 |
|
|
% Change |
|
2025 |
|
|
2024 |
|
% Change |
|||||||
Revenue |
$ |
2,400 |
|
|
$ |
2,388 |
|
|
1 |
|
|
$ |
7,080 |
|
|
$ |
6,939 |
|
2 |
|
Costs and expenses: |
|
|
|
|
|
|
|
|
|
|
|
|||||||||
Cost of sales |
|
683 |
|
|
|
701 |
|
|
(3 |
) |
|
|
1,954 |
|
|
|
2,012 |
|
(3 |
) |
Selling, general and administrative expenses |
|
579 |
|
|
|
565 |
|
|
2 |
|
|
|
1,759 |
|
|
|
1,693 |
|
4 |
|
Research and development expenses |
|
170 |
|
|
|
167 |
|
|
2 |
|
|
|
499 |
|
|
|
500 |
|
— |
|
Amortization of intangible assets |
|
32 |
|
|
|
35 |
|
|
(9 |
) |
|
|
97 |
|
|
|
107 |
|
(9 |
) |
Restructuring charges and certain acquisition and divestiture-related costs |
|
4 |
|
|
|
5 |
|
|
(20 |
) |
|
|
34 |
|
|
|
51 |
|
(33 |
) |
Interest expense, net of capitalized interest |
|
58 |
|
|
|
57 |
|
|
2 |
|
|
|
165 |
|
|
|
174 |
|
(5 |
) |
Other (income)/deductions–net |
|
(13 |
) |
|
|
(16 |
) |
|
(19 |
) |
|
|
(27 |
) |
|
|
1 |
|
* |
|
Income before provision for taxes on income |
|
887 |
|
|
|
874 |
|
|
1 |
|
|
|
2,599 |
|
|
|
2,401 |
|
8 |
|
Provision for taxes on income |
|
166 |
|
|
|
182 |
|
|
(9 |
) |
|
|
529 |
|
|
|
486 |
|
9 |
|
Net income before allocation to noncontrolling interests |
|
721 |
|
|
|
692 |
|
|
4 |
|
|
|
2,070 |
|
|
|
1,915 |
|
8 |
|
Less: Net income/(loss) attributable to noncontrolling interests |
|
— |
|
|
|
10 |
|
|
* |
|
— |
|
|
|
10 |
|
* |
|||
Net income attributable to Zoetis Inc. |
$ |
721 |
|
|
$ |
682 |
|
|
6 |
|
|
$ |
2,070 |
|
|
$ |
1,905 |
|
9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||
Earnings per share attributable to Zoetis—basic |
$ |
1.63 |
|
|
$ |
1.51 |
|
|
8 |
|
|
$ |
4.65 |
|
|
$ |
4.18 |
|
11 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||
Earnings per share attributable to Zoetis—diluted |
$ |
1.63 |
|
|
$ |
1.50 |
|
|
9 |
|
|
$ |
4.65 |
|
|
$ |
4.18 |
|
11 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||
Weighted-average shares used to calculate earnings per share |
|
|
|
|
|
|
|
|
|
|
|
|||||||||
Basic |
|
442.9 |
|
|
|
452.9 |
|
|
|
|
|
445.2 |
|
|
|
455.4 |
|
|
||
Diluted |
|
443.2 |
|
|
|
453.5 |
|
|
|
|
|
445.6 |
|
|
|
456.1 |
|
|
||
(a) The condensed consolidated statements of income present the three and nine months ended September 30, 2025 and 2024. Subsidiaries operating outside the United States are included for the three and nine months ended August 31, 2025 and 2024.
* Calculation not meaningful. |
||||||||||||||||||||
ZOETIS INC. RECONCILIATION OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION CERTAIN LINE ITEMS (UNAUDITED) (millions of dollars, except per share data) |
||||||||||||||||||||
|
|
Three Months Ended September 30, 2025 |
||||||||||||||||||
|
|
GAAP Reported(a) |
|
Purchase Accounting Adjustments |
|
Acquisition and Divestiture- Related Costs(1) |
|
Certain Significant Items(2) |
|
Non-GAAP Adjusted(b) |
||||||||||
Cost of sales |
|
$ |
683 |
|
|
$ |
(1 |
) |
|
$ |
— |
|
|
$ |
— |
|
|
$ |
682 |
|
Gross profit |
|
|
1,717 |
|
|
|
1 |
|
|
|
— |
|
|
|
— |
|
|
|
1,718 |
|
Selling, general and administrative expenses |
|
|
579 |
|
|
|
(2 |
) |
|
|
— |
|
|
|
(7 |
) |
|
|
570 |
|
Amortization of intangible assets |
|
|
32 |
|
|
|
(28 |
) |
|
|
— |
|
|
|
— |
|
|
|
4 |
|
Restructuring charges and certain acquisition and divestiture-related costs |
|
|
4 |
|
|
|
— |
|
|
|
— |
|
|
|
(4 |
) |
|
|
— |
|
Other (income)/deductions–net |
|
|
(13 |
) |
|
|
— |
|
|
|
— |
|
|
|
4 |
|
|
|
(9 |
) |
Income before provision for taxes on income |
|
|
887 |
|
|
|
32 |
|
|
|
— |
|
|
|
7 |
|
|
|
926 |
|
Provision for taxes on income |
|
|
166 |
|
|
|
8 |
|
|
|
— |
|
|
|
(2 |
) |
|
|
172 |
|
Net income attributable to Zoetis |
|
|
721 |
|
|
|
24 |
|
|
|
— |
|
|
|
9 |
|
|
|
754 |
|
Earnings per common share attributable to Zoetis–diluted |
|
|
1.63 |
|
|
|
0.05 |
|
|
|
— |
|
|
|
0.02 |
|
|
|
1.70 |
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
|
|
Three Months Ended September 30, 2024 |
||||||||||||||||||
|
|
GAAP Reported(a) |
|
Purchase Accounting Adjustments |
|
Acquisition and Divestiture- Related Costs(1) |
|
Certain Significant Items(2) |
|
Non-GAAP Adjusted(b) |
||||||||||
Cost of sales |
|
$ |
701 |
|
|
$ |
(1 |
) |
|
$ |
— |
|
|
$ |
(1 |
) |
|
$ |
699 |
|
Gross profit |
|
|
1,687 |
|
|
|
1 |
|
|
|
— |
|
|
|
1 |
|
|
|
1,689 |
|
Selling, general and administrative expenses |
|
|
565 |
|
|
|
(3 |
) |
|
|
— |
|
|
|
(2 |
) |
|
|
560 |
|
Research and development expenses |
|
|
167 |
|
|
|
(1 |
) |
|
|
— |
|
|
|
— |
|
|
|
166 |
|
Amortization of intangible assets |
|
|
35 |
|
|
|
(30 |
) |
|
|
— |
|
|
|
— |
|
|
|
5 |
|
Restructuring charges and certain acquisition and divestiture-related costs |
|
|
5 |
|
|
|
— |
|
|
|
(7 |
) |
|
|
2 |
|
|
|
— |
|
Income before provision for taxes on income |
|
|
874 |
|
|
|
35 |
|
|
|
7 |
|
|
|
1 |
|
|
|
917 |
|
Provision for taxes on income |
|
|
182 |
|
|
|
8 |
|
|
|
2 |
|
|
|
(1 |
) |
|
|
191 |
|
Net income attributable to Zoetis |
|
|
682 |
|
|
|
27 |
|
|
|
5 |
|
|
|
2 |
|
|
|
716 |
|
Earnings per common share attributable to Zoetis–diluted |
|
|
1.50 |
|
|
|
0.06 |
|
|
|
0.01 |
|
|
|
0.01 |
|
|
|
1.58 |
|
(a) The condensed consolidated statements of income present the three months ended September 30, 2025 and 2024. Subsidiaries operating outside the United States are included for the three months ended August 31, 2025 and 2024.
(b) Non-GAAP adjusted net income and its components and non-GAAP adjusted diluted EPS are not, and should not be viewed as, substitutes for U.S. GAAP net income and its components and diluted EPS. Despite the importance of these measures to management in goal setting and performance measurement, non-GAAP adjusted net income and its components and non-GAAP adjusted diluted EPS are non-GAAP financial measures that have no standardized meaning prescribed by U.S. GAAP and, therefore, have limits in their usefulness to investors. Because of the non-standardized definitions, non-GAAP adjusted net income and its components and non-GAAP adjusted diluted EPS (unlike U.S. GAAP net income and its components and diluted EPS) may not be comparable to the calculation of similar measures of other companies. Non-GAAP adjusted net income and its components, and non-GAAP adjusted diluted EPS are presented solely to permit investors to more fully understand how management assesses performance.
See Notes to Reconciliation of GAAP Reported to Non-GAAP Adjusted Information for note (1) and (2). |
||||||||||||||||||||
ZOETIS INC. RECONCILIATION OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION CERTAIN LINE ITEMS (UNAUDITED) (millions of dollars, except per share data) |
||||||||||||||||||||
|
|
Nine Months Ended September 30, 2025 |
||||||||||||||||||
|
|
GAAP Reported(a) |
|
Purchase Accounting Adjustments |
|
Acquisition and Divestiture- Related Costs(1) |
|
Certain Significant Items(2) |
|
Non-GAAP Adjusted(b) |
||||||||||
Cost of sales |
|
$ |
1,954 |
|
|
$ |
(3 |
) |
|
$ |
— |
|
|
$ |
(2 |
) |
|
$ |
1,949 |
|
Gross profit |
|
|
5,126 |
|
|
|
3 |
|
|
|
— |
|
|
|
2 |
|
|
|
5,131 |
|
Selling, general and administrative expenses |
|
|
1,759 |
|
|
|
(8 |
) |
|
|
— |
|
|
|
(22 |
) |
|
|
1,729 |
|
Research and development expenses |
|
|
499 |
|
|
|
(2 |
) |
|
|
— |
|
|
|
— |
|
|
|
497 |
|
Amortization of intangible assets |
|
|
97 |
|
|
|
(84 |
) |
|
|
— |
|
|
|
— |
|
|
|
13 |
|
Restructuring charges and certain acquisition and divestiture-related costs |
|
|
34 |
|
|
|
— |
|
|
|
(1 |
) |
|
|
(33 |
) |
|
|
— |
|
Other (income)/deductions–net |
|
|
(27 |
) |
|
|
— |
|
|
|
— |
|
|
|
(3 |
) |
|
|
(30 |
) |
Income before provision for taxes on income |
|
|
2,599 |
|
|
|
97 |
|
|
|
1 |
|
|
|
60 |
|
|
|
2,757 |
|
Provision for taxes on income |
|
|
529 |
|
|
|
22 |
|
|
|
— |
|
|
|
7 |
|
|
|
558 |
|
Net income attributable to Zoetis |
|
|
2,070 |
|
|
|
75 |
|
|
|
1 |
|
|
|
53 |
|
|
|
2,199 |
|
Earnings per common share attributable to Zoetis–diluted |
|
|
4.65 |
|
|
|
0.16 |
|
|
|
— |
|
|
|
0.12 |
|
|
|
4.93 |
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
|
|
Nine Months Ended September 30, 2024 |
||||||||||||||||||
|
|
GAAP Reported(a) |
|
Purchase Accounting Adjustments |
|
Acquisition and Divestiture- Related Costs(1) |
|
Certain Significant Items(2) |
|
Non-GAAP Adjusted(b) |
||||||||||
Cost of sales |
|
$ |
2,012 |
|
|
$ |
(3 |
) |
|
$ |
— |
|
|
$ |
(1 |
) |
|
$ |
2,008 |
|
Gross profit |
|
|
4,927 |
|
|
|
3 |
|
|
|
— |
|
|
|
1 |
|
|
|
4,931 |
|
Selling, general and administrative expenses |
|
|
1,693 |
|
|
|
(9 |
) |
|
|
— |
|
|
|
(2 |
) |
|
|
1,682 |
|
Research and development expenses |
|
|
500 |
|
|
|
(2 |
) |
|
|
— |
|
|
|
— |
|
|
|
498 |
|
Amortization of intangible assets |
|
|
107 |
|
|
|
(93 |
) |
|
|
— |
|
|
|
— |
|
|
|
14 |
|
Restructuring charges and certain acquisition and divestiture-related costs |
|
|
51 |
|
|
|
— |
|
|
|
(12 |
) |
|
|
(39 |
) |
|
|
— |
|
Other (income)/deductions–net |
|
|
1 |
|
|
|
— |
|
|
|
— |
|
|
|
(35 |
) |
|
|
(34 |
) |
Income before provision for taxes on income |
|
|
2,401 |
|
|
|
107 |
|
|
|
12 |
|
|
|
77 |
|
|
|
2,597 |
|
Provision for taxes on income |
|
|
486 |
|
|
|
24 |
|
|
|
3 |
|
|
|
13 |
|
|
|
526 |
|
Net income attributable to Zoetis |
|
|
1,905 |
|
|
|
83 |
|
|
|
9 |
|
|
|
64 |
|
|
|
2,061 |
|
Earnings per common share attributable to Zoetis–diluted |
|
|
4.18 |
|
|
|
0.18 |
|
|
|
0.02 |
|
|
|
0.14 |
|
|
|
4.52 |
|
(a) The condensed consolidated statements of income present the nine months ended September 30, 2025 and 2024. Subsidiaries operating outside the United States are included for the nine months ended August 31, 2025 and 2024.
(b) Non-GAAP adjusted net income and its components and non-GAAP adjusted diluted EPS are not, and should not be viewed as, substitutes for U.S. GAAP net income and its components and diluted EPS. Despite the importance of these measures to management in goal setting and performance measurement, non-GAAP adjusted net income and its components and non-GAAP adjusted diluted EPS are non-GAAP financial measures that have no standardized meaning prescribed by U.S. GAAP and, therefore, have limits in their usefulness to investors. Because of the non-standardized definitions, non-GAAP adjusted net income and its components and non-GAAP adjusted diluted EPS (unlike U.S. GAAP net income and its components and diluted EPS) may not be comparable to the calculation of similar measures of other companies. Non-GAAP adjusted net income and its components, and non-GAAP adjusted diluted EPS are presented solely to permit investors to more fully understand how management assesses performance.
See Notes to Reconciliation of GAAP Reported to Non-GAAP Adjusted Information for notes (1) and (2). |
||||||||||||||||||||
Contacts
Media:
Jennifer Albano
1-862-399-0810 (o)
jennifer.albano@zoetis.com
Laura Panza
1-973-975-5176 (o)
laura.panza@zoetis.com
Investor:
Steve Frank
1-973-822-7141 (o)
steve.frank@zoetis.com
Nick Soonthornchai
1-973-443-2792 (o)
nick.soonthornchai@zoetis.com
Read full story here
